Use of a liquid nicotine delivery product to promote smoking cessation

BMC Public Health

Volumn 10, Issue , 2010, Pages

  Geimer, Nicholas ^a   Olson, Carl E ^b   Baumgarten, Deborah ^b   Kepner, James L ^c   Mahoney, Martin C ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Medical College of Wisconsin   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NICOTINE;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; SMOKING; SMOKING CESSATION; SOLUTION AND SOLUBILITY;

ADULT; CARBON MONOXIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PHARMACEUTICAL SOLUTIONS; SMOKING; SMOKING CESSATION; YOUNG ADULT;

EID: 77951433452     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-155     Document Type: Article

References (14)

1. Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008 57 45 1226 1228 19008791
2. Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morb Mortal Wkly Rep 2009 58 44 1227 1232 19910909
3. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. TB Baker ME Piper DE McCarthy DM Bolt SS Smith SY Kim S Colby D Conti GA Giovino D Hatsukami, et al. Nicotine Tob Res 2007 9 Suppl 4 555 570 18067032
4. Strategies for smoking cessation: what is new and what works? KM Cummings MC Mahoney, Expert Review of Respiratory Medicine 2008 2 201 213 10.1586/17476348.2.2.201 (Pubitemid 351982830)
5. A clinical blueprint to accelerate the elimination of tobacco use. MC Fiore CR Jaen, Jama 2008 299 17 2083 2085 10.1001/jama.299.17.2083 18460668
6. Treating Tobacco Use and Dependence: 2008 Update. MC Fiore CR Jaen TB Baker, et al. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service 2008
7. Nicotine replacement therapy for smoking cessation. LF Stead R Perera C Bullen D Mant T Lancaster, Cochrane Database Syst Rev 2008 1 D000146 18253970
8. Antidepressants for smoking cessation. JR Hughes LF Stead T Lancaster, Cochrane database of systematic reviews (Online) 2007 1 D000031 17253443
9. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. D Gonzales SI Rennard M Nides C Oncken S Azoulay CB Billing EJ Watsky J Gong KE Williams KR Reeves, JAMA 2006 296 1 47 55 10.1001/jama.296.1.47 16820546
10. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. DE Jorenby JT Hays NA Rigotti S Azoulay EJ Watsky KE Williams CB Billing J Gong KR Reeves, JAMA 2006 296 1 56 63 10.1001/jama.296.1.56 16820547
11. Smoking cessation trials targeted to racial and economic minority groups. NL Benowitz, JAMA 2002 288 4 497 499 10.1001/jama.288.4.497 12132983
12. Measures of abstinence in clinical trials: issues and recommendations. JR Hughes JP Keely RS Niaura DJ Ossip-Klein RL Richmond GE Swan, Nicotine Tob Res 2003 5 1 13 25 12745503 (Pubitemid 36285465)
13. Adverse effects with use of nicotine replacement therapy among quitline clients. DJ Ossip SM Abrams MC Mahoney D Sall KM Cummings, Nicotine Tob Res 2009 11 4 408 417 10.1093/ntr/ntp005 19325134
14. Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking. JE Henningfield ED London NL Benowitz, JAMA 1990 263 15 2049 2050 10.1001/jama.263.15.2049 2319665